Fluvoxamine for early treatment of COVID-19: the STOP COVID clinical trials (Eric Lenze, MD)

NIH Collaboratory | August 20, 2021

While using Fluvoxamine to treat anxiety in patients with Wolfram Syndrome, Dr. Reiersen from Washington University, St. Louis learned that Fluvoxamine (Luvox) reduced inflammation and interfered with viral function. Watch this detailed 55 minute presentation by Dr. Eric Lenze as guest of the NIH Grand Rounds program.

Be the First to Know

Sign up to get updates when we add new off-label treatments, articles, videos, and clinical trials!